| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T101 |
0-4 |
Sentence |
denotes |
2.2. |
| T102 |
5-40 |
Sentence |
denotes |
Galidesivir (Immucillin-A, BCX4430) |
| T103 |
41-154 |
Sentence |
denotes |
Galidesivir is an adenosine nucleoside analog (Figure 3) that is an active site inhibitor of RdRp (EC50 < 50 µM). |
| T104 |
155-294 |
Sentence |
denotes |
Similar to remdesivir, it is a prodrug that is metabolized by cellular kinases to the corresponding active form of nucleoside triphosphate. |
| T105 |
295-458 |
Sentence |
denotes |
The triphosphate form binds to the active site of the viral enzyme and gets incorporated into the growing viral RNA chain resulting in premature chain termination. |
| T106 |
459-620 |
Sentence |
denotes |
The drug is being developed by BioCryst, U.S., and being tested in a phase 1 clinical trial for COVID-19 or Yellow Fever in Brazil in collaboration with the U.S. |
| T107 |
621-664 |
Sentence |
denotes |
NIAID (NCT03891420; n = 132) [44,45,46,47]. |
| T108 |
665-864 |
Sentence |
denotes |
The drug is used parenterally and has demonstrated a broad-spectrum, showing in vitro antiviral activity against at least 20 RNA viruses across eight different virus families including coronaviruses. |
| T109 |
865-1016 |
Sentence |
denotes |
In animal studies, the drug was effective in protecting against dangerous viruses such as Zika, Yellow Fever, Marburg, and Ebola viruses [44,45,46,47]. |
